for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beigene Ltd

6160.HK

Latest Trade

102.70HKD

Change

-3.50(-3.30%)

Volume

115,700

Today's Range

102.00

 - 

107.10

52 Week Range

69.50

 - 

132.00

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
106.20
Open
106.20
Volume
115,700
3M AVG Volume
2.65
Today's High
107.10
Today's Low
102.00
52 Week High
132.00
52 Week Low
69.50
Shares Out (MIL)
1,001.70
Market Cap (MIL)
106,380.90
Forward P/E
-15.06
Dividend (Yield %)
--

Next Event

Q4 2019 Beigene Ltd Earnings Release

Latest Developments

More

Felix Baker Reports 15.8% Stake In Beigene As Of January 2

Leap Therapeutics And BeiGene Announce Exclusive Option And License Agreement, Co Announces $27 Mln Equity Financing

China National Medical Products Administration Approves Tislelizumab For Patients With Classical Hodgkin's Lymphoma With At Least 2 Therapies

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beigene Ltd

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Industry

Biotechnology & Drugs

Contact Info

C/O Mourant Governance Services (Cayman)

94 Solaris Avenue, Camana Bay

+1.345.9494123

Executive Leadership

John Victor Oyler

Executive Chairman of the Board, Chief Executive Officer

Xiaobin Wu

General Manager - China, President

Howard Liang

Chief Financial Officer and Chief Strategy Officer

Jane Huang

Chief Medical Officer, Hematology

Hing Ling Chau

Company Secretary

Key Stats

1.77 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019(E)

0.4K
EPS (USD)

2018

-0.930

2019(E)

-0.896
Price To Earnings (TTM)
--
Price To Sales (TTM)
31.85
Price To Book (MRQ)
8.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
20.00
LT Debt To Equity (MRQ)
19.94
Return on Investment (TTM)
-43.49
Return on Equity (TTM)
-38.60

Latest News

Latest News

BeiGene lung cancer treatment meets main goal in late-stage study

BeiGene Ltd said on Tuesday its cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.

BeiGene cancer drug fails in study against AbbVie: J&J's Imbruvica

BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc. The results come merely a month after BeiGene scored a win with Brukinsa's approval to treat patients...

BeiGene drug fails main goal in late-stage study against AbbVie-J&J rival Imbruvica

BeiGene Ltd said on Monday a late-stage trial testing its recently approved cancer treatment Brukinsa did not meet the main goal of proving superior to Imbruvica, a rival medicine from Johnson & Johnson and AbbVie Inc.

BeiGene prices lymphoma drug at $12,935 for a 30-day supply

China-based drugmaker BeiGene Ltd on Friday priced its drug, Brukinsa, to treat a rare form of lymphoma at $12,935 for a 30-day supply.

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd's lymphoma treatment, validating the China-based drugmaker's strategy of largely using data from trials held outside the United States to file for approval.

BeiGene drug wins U.S. FDA approval for rare form of lymphoma

The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd's lymphoma treatment, validating the China-based drugmaker's strategy of largely using data from trials held outside the United States to file for approval.

Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China

Amgen Inc <AMGN.O> said on Thursday it will take a 20.5% stake in BeiGene Ltd <6160.HK> in a deal to expand the California-based biotechnology company's presence in China, the world's second largest pharmaceutical market.

Amgen to take 20.5% stake in BeiGene to expand in China

Amgen Inc said on Thursday it will acquire a 20.5% stake in BeiGene Ltd in a deal that will enable the California-based biotechnology company to expand its presence in China, the world's second largest pharmaceutical market.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up